|Bid||116.72 x 800|
|Ask||116.77 x 800|
|Day's range||116.70 - 118.20|
|52-week range||86.16 - 128.54|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||36.74|
|Earnings date||14-Jul-2021 - 19-Jul-2021|
|Forward dividend & yield||1.80 (1.52%)|
|1y target est||135.84|
U.S. stock markets closed lower on Tuesday as concerns over the rising COVID-19 cases globally led to weakness in reopening stocks with the U.S. State Department also set to issue international travel warnings
Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.
Abbott (ABT) delivered earnings and revenue surprises of -0.75% and -3.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?